Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug
10.1097/01.ftd.0000194497.55269.d9
Saved in:
Main Authors: | Tham, L.-S., Lee, H.-S., Wang, L., Yong, W.-P., Fan, L., Ong, A.-B., Sukri, N., Soo, R., Lee, S.-C., Goh, B.-C. |
---|---|
Other Authors: | PHARMACY |
Format: | Article |
Published: |
2014
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/106101 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers
by: Yong, W.-P., et al.
Published: (2014) -
Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients
by: Lee, H.S., et al.
Published: (2012) -
Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients
by: Lee, H.S., et al.
Published: (2014) -
Simultaneous determination of probe drugs, metabolites, inhibitors and inducer in human plasma by liquid chromatography/tandem mass spectrometry and its application to pharmacokinetic study
by: Hee, K.H., et al.
Published: (2016) -
Development of a simple dissolution testing method for Ketoconazole tablet
by: Kanokwan Prasitporn, et al.
Published: (2010)